For the consolidated net sales for the fiscal year ending July 2026, YoY decline overall; Recovery Business grows, Anti-Aging Business declines. Operating income exceed the revised plan. For 2027\/07, company-wide sales are expected to be at the prior year\u2019s level, but operating income is anticipated to decline due to greater brand investment and new product launches. Segment-wise, continued growth focus on duo-related promotions and expansion of Recovery, with\u80b2\u6210 brands such as Canadel and Clayence continuing to be developed.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4934","jir_company_name":"Premier Anti-Aging Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4934-20260914-02.pdf","jir_short_summary":"For the consolidated net sales for the fiscal year ending July 2026, YoY decline overall; Recovery Business grows, Anti-Aging Business declines. Operating income exceed the revised plan. For 2027\/07, company-wide sales are expected to be at the prior year\u2019s level, but operating income is anticipated to decline due to greater brand investment and new product launches. Segment-wise, continued growth focus on duo-related promotions and expansion of Recovery, with\u80b2\u6210 brands such as Canadel and Clayence continuing to be developed.","jir_summary":"### Overview of Performance\nFor the fiscal year ending July 2026, consolidated net sales are supported by growth in the Recovery Business, but decline due to weaker Anti-Aging product sales. Operating income progressed as costs were controlled and promotional investments for new products exceeded plans. Segments continue to expand promotions for Duo and broaden wholesale\/EC channels;\u80b2\u6210 brands such as Canadel and Clayence remain in development. Recovery Business maintains growth through offline sales expansion. For the fiscal year ending July 2027, company-wide sales are assumed to be at the previous year's level, but operating income is expected to decline due to expanded brand investments and new product launches.\n\n### Outlook and Strategy\nProceed with a full-scale rollout of Skin for Longevity as the core of the skincare portfolio. By optimizing the channel mix across offline and digital and strengthening CRM, aim to improve LTV and brand awareness. The Recovery Business will continue to lead market growth. Financially, continue to optimize advertising\/promo expenses and reduce fixed costs, with plans to balance growth investments and profitability in 2027.","jir_financial_highlights":"Sales: 13,883 (YoY decrease of 13.0% (FY2025 result 16,160 \u2192 FY2026 result 13,883))\nOperating income: 494 (YoY \u25b3122)\nNet income attributable to owners of parent: 364 (YoY \u25b3107)","jir_category":"","jir_hashtags":"#PremierAntiAging, #FinancialSummary, #SegmentBreakdown, # Skin for Longevity, #Duo","jir_key_figures":"Sales: 13,883 million yen\nOperating income: 494 million yen\nNet income attributable to owners of parent: 364 million yen","jir_meta_title":"\u3010Premier Anti-Aging\u3011Financial Summary | Results for FY2026 and Outlook for 2027","jir_meta_description":"Premier Anti-Aging FY2026 July results highlights. Sales decline YoY, segment trends, outlook for 2027, growth strategies for Recovery and Anti-Aging, and sustainability information summarized for IR materials.","jir_og_title":"\u3010Premier Anti-Aging\u3011Financial Summary | Results for FY2026","jir_og_description":"Overview of FY2026 results and 2027 outlook. Segment trends,\u80b2\u6210 brands such as Duo and Canadel status, Recovery growth and impact of advertising investments.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":59723,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-113809","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n